Hagop Kantarjian joins Actinium Pharmaceuticals’ clinical advisory board
Wednesday, October 3, 2012
Actinium Pharmaceuticals (API), a New York-based biopharmaceutical company focused on immunotherapeutics, has appointed Hagop Kantarjian, MD, to the company’s clinical advisory board.
Kantarjian, who heads the largest leukemia service in the world at MD Anderson Cancer Center in Houston, Texas, will help API in developing its clinical stage drug candidates in the field of hematologic oncology, Actimab-A and Iomab-B, as well as other earlier stage products.
“[Kantarigian] is one of the foremost blood cancer experts in the world and has achieved many esteemed certifications, honors and awards over his career,” said Jack Talley, CEO of Actinium Pharmaceuticals. “Actinium has assembled a superb team of clinical experts to help guide our programs to their next milestones and ultimately expand the number of patients who are successfully in remission for acute myeloid leukemia or able to have a successful bone marrow transplant due to our product candidates.”